Sandoz intends to seek regulatory approval for its aflibercept biosimilar in the US and EU in the coming months.
List view / Grid view
Privately-owned Grünenthal estimates the Nebido brand will add about €100 million to its EBITDA in 2023.
BlueRock Therapeutics LP has established a new site for cell therapy innovation on Bayer’s campus in Berlin, Germany.
Here we run down four new research collaborations in the cell and gene therapy sector, announced by Bayer, BMS, Pfizer and Moderna.
Bayer have announced that Professor Dominik Ruettinger will be its new Head of Research and Early Development for Oncology, effective 1 October 2021.
Bayer has signed a collaboration and services agreement with CureVac for the development of CVnCoV, a COVID-19 vaccine currently in late-stage trials.
The producers of hydroxychloroquine have stated they will donate 130 million doses if the drug is approved as a treatment for the COVID-19 coronavirus.
A study evaluating the efficacy and safety of vericiguat, a treatment for patients with worsening chronic heart failure, has met the primary efficacy endpoint.
Five pharma companies have filed a complaint in Canadian court over new rules intended to lower the price of drugs in the country.
The worldwide trade of the cephalosporin class of antibiotics will increase to $14.1 billion by the end of 2025.
The EMA has announced its approval for marketing authorisation in the EU for Vitrakvi (larotrectinib), used to treat solid tumours with a specific gene mutation.
A new report predicts that the global diabetes drug market will rise to US$58.4 billion by 2025.
NICE has released a Final Appraisal Document recommending Nexavar for the treatment of patients with advanced hepatocellular carcinoma...